Prochlorperazine
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1505 publications
Preparation and evaluation of Prochlorperazine Maleate loaded nanostructured lipid carrier for the treatment of schizophrenia.
Journal: Therapeutic delivery
Published: May 22, 2026
Successful use of intravenous droperidol in hyperemesis following failure of sequential antiemetic therapy.
Journal: The American journal of emergency medicine
Published: March 04, 2026
Enhancing KCC2 function reduces interictal activity and prevents seizures in temporal lobe epilepsy.
Enhancing KCC2 function reduces interictal activity and prevents seizures in temporal lobe epilepsy.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 03, 2026
Exogenous Sex Hormones and Postoperative Nausea and Vomiting Risk in Transgender Patients.
Journal: Anesthesia and analgesia
Published: February 02, 2026
Pharmaceutical policy and off-label prescribing in pregnancy: A population-based historical cohort study analyzing inequality in access to antiemetics within Australia's Pharmaceutical Benefits Scheme.
Journal: Acta obstetricia et gynecologica Scandinavica
Published: December 09, 2025
Trends in Antipsychotic Drug Use in the United States, 2000-2016.
Journal: Pharmacy (Basel, Switzerland)
Published: December 01, 2025
Preoperative Aprepitant Decreases Postoperative Nausea After Laparoscopic Sleeve Gastrectomy.
Journal: Rhode Island medical journal (2013)
Published: November 24, 2025
2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies.
Journal: Headache
Published: October 20, 2025
Exploring Risk Drugs and Mechanisms in Dystonia: Insights from Pharmacovigilance and Proteogenomics.
Exploring Risk Drugs and Mechanisms in Dystonia: Insights from Pharmacovigilance and Proteogenomics.
Journal: Current neuropharmacology
Published: October 14, 2025
A glycoengineered anti-ROR1 antibody, GE-zilovertamab, selectively enhances antibody-dependent cellular cytotoxicity against chronic lymphocytic leukemia.
Journal: Antibody therapeutics
Published: September 03, 2025
Last Updated: 06/30/2026